Furthermore, in cohort 2 of DESTINY-Lung01, T-DXd (6.4 mg/kg) was used for the treatment of HER2-mutant NSCLC patients, and drug-related pneumonitis occurred in 26% of the 91 patients enrolled, with grade 3 or higher events in 6.6% of patients [21]. Here, ERBB2 is linked to non-small cell lung carcinoma.